Sumitomo Pharma Co., Ltd. (4506) raised its net profit forecast for the fiscal year ending March 2027 by 22.1% to ¥94.0 billion and said it would resume dividends with a year-end payout of ¥15 per share.
For the April-September first half, revenue rose 17.3% from a year earlier to ¥266.5 billion, while core operating profit fell 56.2% to ¥42.1 billion and net profit attributable to owners of the parent fell 61.3% to ¥38.2 billion, or ¥86.48 per share.
The first-half results beat the company's July 31 forecast by ¥15.5 billion in revenue, ¥12.1 billion in core operating profit and ¥12.2 billion in net profit. The company cited strong U.S. sales of overactive bladder drug Gemtesa and a weaker-than-assumed yen, while SG&A and R&D expenses excluding currency effects ran slightly below plan.
The company revised its May 13 full-year guidance and changed its average exchange rate assumption to 157.0 yen per dollar from 155.0 yen:
| Item | Previous | Revised | Change |
|---|---|---|---|
| Revenue | ¥540.0 billion | ¥565.0 billion | 4.6% |
| Core operating profit | ¥91.0 billion | ¥105.0 billion | 15.4% |
| Operating profit | ¥90.0 billion | ¥104.0 billion | 15.6% |
| Net profit | ¥77.0 billion | ¥94.0 billion | 22.1% |
Revised earnings per share stand at ¥211.07. The company expects U.S. sales, led by Gemtesa, to exceed plan, while also projecting higher sales-related expenses. Against the prior-year results, the new forecast implies revenue growth of 24.6% and a 12.0% decline in net profit.
Sumitomo Pharma had left its dividend forecast undetermined, prioritizing financial soundness and growth investment. Citing first-half progress and its outlook, it set a year-end dividend of ¥15 per share, with no interim dividend, after paying nothing for the fiscal year ended March 2026. Its equity ratio stood at 50.7% at the end of September, up from 36.4% at the end of March.
The company plans to file its semi-annual securities report on Nov. 2, 2026.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。